Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis

JAMA - Journal of the American Medical Association

Volumn 313, Issue 3, 2015, Pages 275-284

  Burt, Richard K ^a   Balabanov, Roumen ^b   Han, Xiaoqiang ^a   Sharrack, Basil ^c   Morgan, Amy ^a   Quigley, Kathleeen ^a   Yaung, Kim ^a   Helenowski, Irene B ^a   Jovanovic, Borko ^a   Spahovic, Dzemila ^a   Arnautovic, Indira ^a   Lee, Daniel C ^a   Benefield, Brandon C ^a   Futterer, Stephen ^a   Oliveira, Maria Carolina ^d   Burman, Joachim ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; CEFEPIME; CLADRIBINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DACLIZUMAB; DIURETIC AGENT; FILGRASTIM; FINGOLIMOD; FLUCONAZOLE; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VANCOMYCIN; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DRUG SUBSTITUTION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FEVER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE SCORE; NEUROLOGIC DISEASE; NEUROLOGIC DISEASE ASSESSMENT; NEUROLOGIC RATING SCALE SCORE; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PLASMAPHERESIS; PROGRESSION FREE SURVIVAL; RATING SCALE; RECURRENCE FREE SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; BRAIN; CLASSIFICATION; DISABILITY; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; BRAIN; CYCLOPHOSPHAMIDE; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT (HEALTH CARE); TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84921451352     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.17986     Document Type: Article

References (39)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938-952.
2. Cohen JA, Rudrick RA. Aspects of multiple sclerosis that relate to trial design and clinical management. In: Cohen JA, Rudrick RA, eds. Multiple Sclerosis Therapeutics. Boca Raton, FL: Taylor & Francis; 2007:3-23.
3. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696-1702.
4. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77(8):918-926.
5. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med. 2007;356(25):2622-2629.
6. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366(4):339-347.
7. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012;308(3):247-256.
8. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254-260.
9. Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler. 2011;17(8):970-979.
10. Devonshire V, Havrdova E, Radue EW, et al; FREEDOMS study group. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol. 2012;11(5):420-428.
11. Kappos L, Radue EW, O'Connor P, et al FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
12. Burt RK, Loh Y, PearceW, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA. 2008; 299(8):925-936.
13. Abrahamsson SV, Angelini DF, Dubinsky AN, et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain. 2013;136(pt 9):2888-2903.
14. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201(5): 805-816.
15. Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study [published correction appears in Lancet Neurol. 2009;8(4):309]. Lancet Neurol. 2009;8(3):244-253.
16. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005;58(6):840-846.
17. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
18. Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14:58.
19. Sharrack B, Hughes RA. Clinical scales for multiple sclerosis. J Neurol Sci. 1996;135(1):1-9.
20. Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS, Oldstone MB. A Neurologic Rating Scale (NRS) for use in multiple sclerosis. Neurology. 1984;34(10):1368-1372.
21. Koziol JA, Lucero A, Sipe JC, Romine JS, Beutler E. Responsiveness of the Scripps Neurologic Rating Scale during a multiple sclerosis clinical trial. Can J Neurol Sci. 1999;26(4):283-289.
22. Yandall BS. Practical Data Analysis for Designed Experiments. New York, NY: Taylor & Francis Group; 1997.
23. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G; National Multiple Sclerosis Society. Multiple Sclerosis Functional Composite (MSFC): Administrative and Scoring Manual, revised October 2001. http://main.nationalmssociety.org /docs/HOM/MSFC-Manual-and-Forms.pdf. Accessibility verified December 23, 2014.
24. Polman CH, O'Connor PW, Havrdova E, et al AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
25. Rudick RA, Stuart WH, Calabresi PA, et al SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923.
26. Butzkueven H, Kappos L, Pellegrini F, et al TYSABRI Observational Program (TOP) Investigators. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85(11):1190-1197.
27. Cohen JA, Coles AJ, Arnold DL, et al; CARE-MS I investigators. Alemtuzumab vs interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856): 1819-1828.
28. Coles AJ, Twyman CL, Arnold DL, et al; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856): 1829-1839.
29. Rudick RA,Miller D, Hass S, et al AFFIRM and SENTINEL Investigators. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007;62(4):335-346.
30. Norman GR, Sloan JA,Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582-592.
31. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4(11):2377-2383.
32. Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011; 118(24):6299-6305.
33. Loh Y, Oyama Y, Statkute L, et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood. 2007;109(6):2643-548.
34. Daniels GH, Vladic A, Brinar V, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab. 2014;99 (1):80-89.
35. Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. doi:10.1001/jamaneurol.2014.3780.
36. Zeiner A, HolzerM, Sterz F, et al. Hyperthermia after cardiac arrest is associated with an unfavorable neurologic outcome. Arch Intern Med. 2001;161(16):2007-2012.
37. Albrecht RF II,Wass CT, Lanier WL. Occurrence of potentially detrimental temperature alterations in hospitalized patients at risk for brain injury. Mayo Clin Proc. 1998;73(7):629-635.
38. Bol Y, Smolders J, Duits A, Lange IM, Romberg-Camps M, Hupperts R. Fatigue and heat sensitivity in patients with multiple sclerosis. Acta Neurol Scand. 2012;126(6):384-389.
39. Morris ES, Sharrack B, Dalley CD, Snowden JA. The Uhthoff phenomenon: a potential post transplant complication in advanced progressive multiple sclerosis. Bone Marrow Transplant. 2007; 40(10):1003-1004.